UBS AM
CAPR icon

UBS AM’s Capricor Therapeutics CAPR Stock Holding History

UBS AM’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Sell
74,430
-1,947
-3% -$59K ﹤0.01% 2099
2026
Q1 		$2.32M Buy
76,377
+76,125
+30,208% +$2.03M ﹤0.01% 1967
2025
Q4 		$7.27K Buy
+252
New +$3.29K ﹤0.01% 2913
2025
Q3 		– Sell
-92,176
Closed -$915K – 2340
2025
Q2 		$915K Buy
92,176
+33,010
+56% +$349K ﹤0.01% 2406
2025
Q1 		$561K Buy
59,166
+25,668
+77% +$356K ﹤0.01% 2475
2024
Q4 		$462K Buy
+33,498
New +$587K ﹤0.01% 2564

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM's CAPR Position: Q2 2026 in Review

UBS AM reduced its Capricor Therapeutics (CAPR) stake by 2.5% in Q2 2026, selling an estimated $59K and leaving 74,430 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

UBS AM first reported a position in CAPR in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.32M in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • UBS AM held 74,430 shares of Capricor Therapeutics worth $1.79M as of Q2 2026.
  • UBS AM sold 1,947 Capricor Therapeutics shares in Q2 2026, an estimated $59K.
  • Capricor Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2099 holding.
  • UBS AM first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • UBS AM's Capricor Therapeutics position peaked at $2.32M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.